Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semorinemab (Primary) ; Diagnostic imaging enhancers
Indications Alzheimer's disease
Focus Therapeutic Use
Acronyms LAURIET
Sponsors Genentech

Most Recent Events

22 Jan 2024 According to an AC Immune media release, final open label extension results from the Lauriet trial will be reviewed when they become available and are received in full by AC Immune.
11 Sep 2023 Status changed from active, no longer recruiting to completed.
29 Aug 2023 Results published in the Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com